← Eichor
Condition: Retinitis Pigmentosa Rp Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Retinitis Pigmentosa Rp

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Gene Therapy for RPGR Gene Mutation-associated X-linked Retinitis Pigmentosa
Phase 1/Phase 2 · 1 location(s) · Frontera Therapeutics · NCT06492850InsightRP2 Registry
Phase N/A · 1 location(s) · University of Göttingen · NCT06982417Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degener
Phase N/A · 1 location(s) · Ray Therapeutics, Inc. · NCT06375239Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Caus
Phase N/A · 36 location(s) · Jaeb Center for Health Research · NCT05589714Natural History of Photoreceptor Degeneration in USH1B: Clinical Parameters and Validation of Functional Vision Tests in
Phase N/A · 1 location(s) · Centre Hospitalier National d'Ophtalmologie des Quinze-Vingt · NCT07278843Cell Collection to Study Eye Diseases
Phase N/A · 1 location(s) · National Eye Institute (NEI) · NCT01432847Retinal Imaging in Patients With Inherited Retinal Degenerations
Phase N/A · 1 location(s) · University of California, San Francisco · NCT00254605A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years
Phase 1/Phase 2 · 2 location(s) · Sumitomo Pharma America, Inc. · NCT06891885Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal
Phase N/A · 1 location(s) · Ray Therapeutics, Inc. · NCT07502664Safety and Efficacy of ZVS203e in the Treatment of Retinitis Pigmentosa Caused by RHO Gene Mutation
Phase 1/Phase 2 · 1 location(s) · Chigenovo Co., Ltd · NCT06952842Evaluating a New Peptide Therapy for Retinal Diseases: AMD, Diabetic Retinopathy, and Dystrophies
Phase 1/Phase 2 · 2 location(s) · Ace Cells Lab Limited · NCT06787482Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
Phase 2 · 14 location(s) · jCyte, Inc · NCT06912633Pilot Study of AuTNA I
NA · 1 location(s) · Eye & ENT Hospital of Fudan University · NCT05853107Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa
EARLY_Phase 1 · 2 location(s) · Frontera Therapeutics · NCT05874310Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for NAION
Phase 1 · 2 location(s) · The Foundation for Orthopaedics and Regenerative Medicine · NCT05147701Evaluation of Objective Perimetry Using Chromatic Multifocal Pupillometer
Phase N/A · 1 location(s) · Sheba Medical Center · NCT02014389Global Registry and Natural History Study for Mitochondrial Disorders
Phase N/A · 33 location(s) · LMU Klinikum · NCT05554835ARPKD Database Study
Phase N/A · 6 location(s) · Children's Hospital of Philadelphia · NCT01401998North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)
Phase N/A · 17 location(s) · Columbia University · NCT01694940Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Phase N/A · 2 location(s) · Sanford Health · NCT01793168An Open-label, Dose-ascending Study of IGT001 for Retinitis Pigmentosa
Phase 1 · 1 location(s) · Shanghai General Hospital, Shanghai Jiao Tong University Sch · NCT06936787A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa
Phase 2 · 5 location(s) · Kiora Pharmaceuticals, Inc. · NCT06628947Implementation and Evaluation of a Post-Diagnostic Announcement Protocol at the CRMR RefeRet, Quinze-Vingts Hospital
NA · 1 location(s) · Centre Hospitalier National d'Ophtalmologie des Quinze-Vingt · NCT07292987Brain Stimulation Effects on Orientation and Mobility Skills in Adults With Vision Impairment
NA · 1 location(s) · University of Waterloo · NCT07341763Natural History Study of Patients With EYS-Associated RP
Phase N/A · 1 location(s) · Sensor Technology for Deafblind · NCT07228793Natural History Study of Usher Syndrome ( Light4Deaf )
Phase N/A · 4 location(s) · Centre Hospitalier National d'Ophtalmologie des Quinze-Vingt · NCT04665726Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa
Phase 1/Phase 2 · 3 location(s) · AAVantgarde Bio Srl · NCT06591793Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations i
Phase 1 · 1 location(s) · VeonGen Therapeutics GmbH · NCT06291935Real-World Effects of MC4R Agonist Therapy in BBS and Severe Genetic Obesity
Phase 4 · 1 location(s) · Tom Hühne · NCT07674290Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients
EARLY_Phase 1 · 1 location(s) · Zhongmou Therapeutics · NCT06292650
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.